Synaptogenix Inc — Company Overview, News & Financial Data

Synaptogenix (NASDAQ:SNPX) is focused on developing cutting-edge therapeutics for neurodegenerative diseases like Alzheimer's. The company is leveraging its proprietary technology to enhance synaptic growth and repair, aiming to address the unmet needs in this critical area. One of their primary projects is the development of Bryostatin-1, which has shown promise in stimulating synaptic regeneration and cognitive function in preclinical trials. Synaptogenix's efforts are driven by a commitment to improve the lives of patients and families affected by debilitating neurological conditions. Their objectives include advancing clinical trials, securing regulatory approvals, and ultimately bringing novel treatments to the market.